Everything below concerns melanogenesis. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-12-16. Numbers and descriptions here follow the published literature rather than marketing material.
Melanotan-2 has not received marketing authorisation from major regulatory agencies for any therapeutic indication. Several jurisdictions classify it as a prescription-only medicine or a controlled substance when supplied for human use. Because approved products do not exist, material sold online usually sits outside pharmaceutical supply chains and formal quality oversight. Regulators have issued public notices describing the compound as unapproved. Enforcement varies, and the legal position differs between countries, which complicates any single general statement about its status.
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Unapproved for therapeutic use | No marketing authorisation from major agencies |
| Legal classification | Varies by jurisdiction | Prescription-only or controlled in several countries |
| Common synonyms | Melanotan II; MT-II | Also referenced by catalogue codes |
| Typical analytical method | Reverse-phase HPLC | Often paired with mass spectrometry |
| Primary literature focus | Receptor pharmacology | Pigmentation and melanocortin signalling |
Analytical confirmation of identity relies on mass spectrometry, most often coupled to liquid chromatography. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and provides a purity estimate based on peak area. Electrospray ionization mass spectrometry then confirms the expected molecular mass, while tandem mass spectrometry can map the fragment sequence. For research-grade material, these two techniques together form the standard minimum. Purity figures reported by vendors are frequently not traceable to an independent laboratory.
Independent verification is central to quality control because the compound is not produced under pharmaceutical manufacturing standards. Third-party laboratories can measure purity, identity, residual solvents, and microbial contamination, though the scope of testing varies between services. Reported analyses of vendor samples have shown batch-to-batch variation in peptide content and the presence of truncated or oxidized species. How much of this variation reflects synthesis conditions versus storage and shipping is not well characterized. No harmonized reference standard exists for the material as sold.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
== Treatment eligibility == Many providers use informed consent, whereby someone seeking hormone therapy can sign a statement of informed consent and begin treatment without much gatekeeping. For other providers, eligibility is determined using major diagnostic tools such as ICD-11 or the Diagnostic and Statistical Manual of Mental Disorders (DSM) to classify a patient with gender dysphoria. The Endocrine Society requires physicians that diagnose gender dysphoria and gender incongruence to be trained in psychiatric disorders with competency in ICD-11 and DSM-5. The healthcare provider should also obtain a thorough assessment of the patient's mental health and identify potential psychosocial factors that can affect therapy.
In her reply, Meitner concurred. "At the moment, the interpretation of such a thoroughgoing breakup seems very difficult to me, but in nuclear physics we have experienced so many surprises, that one cannot unconditionally say: 'it is impossible'." On 22 December 1938, Hahn sent a manuscript to Naturwissenschaften reporting their radiochemical results, which were published on 6 January 1939. On 27 December, Hahn telephoned the editor of the Naturwissenschaften and requested an addition to the article, speculating that some platinum group elements previously observed in irradiated uranium, which were originally interpreted as transuranium elements, could in fact be technetium (then called "masurium"), mistakenly believing that the atomic masses had to add up rather than the atomic numbers. By January 1939, he was sufficiently convinced of the formation of light elements that he published a new revision of the article, retracting former claims of observing transuranic elements and neighbours of uranium. As a chemist, Hahn was reluctant to propose a revolutionary discovery in physics, but Meitner and Frisch worked out a theoretical interpretation of nuclear fission, a term appropriated by Frisch from biology. In January and February they published two articles discussing and experimentally confirming their theory.
== Risk of injury == Injuries can happen in activities like yoga and aerobics . Quick, ballistic stretching can cause injury if it is done incorrectly. If a bone, muscle, or any other part is stretched more than its capacity, it may lead to dislocation or muscle pulls. Overstretching can increase chances of injury by stretching the muscle too much. Overstretching could lead to a sprain or strain, which requires rest or even physical therapy to recover from.
Sources: en.wikipedia.org
The oldest known constructed roadways are the stone-paved streets of the city-state of Ur, dating to c. 4,000 BCE, and timber roads leading through the swamps of Glastonbury, England, dating to around the same period. The first long-distance road, which came into use around 3,500 BCE, spanned 2,400 km from the Persian Gulf to the Mediterranean Sea, but was not paved and was only partially maintained. Around 2,000 BCE, the Minoans on the Greek island of Crete built a 50 km road leading from the palace of Gortyn on the south side of the island, through the mountains, to the Palace of Knossos on the north side of the island. Unlike the earlier road, the Minoan road was completely paved. Ancient Minoan private homes had running water. A bathtub virtually identical to modern ones was unearthed at the Palace of Knossos. Several Minoan private homes also had toilets, which could be flushed by pouring water down the drain. The ancient Romans had many public flush toilets, which emptied into an extensive sewage system. The primary sewer in Rome was the Cloaca Maxima; construction began on it in the sixth century BCE, and it is still in use today. The ancient Romans also had a complex system of aqueducts, which were used to transport water across long distances. The first Roman aqueduct was built in 312 BCE. The eleventh and final ancient Roman aqueduct was built in 226 CE. Put together, the Roman aqueducts extended over 450 km, but less than 70 km of this was above ground and supported by arches.
Among these mixed communities, the largest Christian populations in Druze towns are found in Maghar, followed by Isfiya and Peki'in. Conversely, the largest Druze communities in predominantly Christian towns are located in Rameh, followed by Kafr Yasif. Before Israel's occupation, Christians accounted for 12% of the population of the Golan Heights, and they tended to have a high representation in science and in the white collar professions. But a few Christians remain of a much larger community that left the area. In 2010 more than 8,000 Christians lived in Druze-majority towns and cities in Israel, including Daliyat al-Karmel, Ein Qiniyye, Hurfeish, Isfiya, Kisra-Sumei, Majdal Shams, Maghar and Peki'in. Additionally, in 2016, more than 2,700 Druze lived in Rameh and Kafr Yasif, which are Christian-majority towns located in the Galilee region, and more than 12,000 Christians and 9,800 Druze lived Abu Snan and Shefa-Amr, which have a Muslim majority. Before 1948, some Druze towns such as Beitegen, Julis, Sajur and Yarka were inhabited by small Christian communities.
The cell nucleus is the largest organelle in the animal cells and many other eukaryotic cells. It houses the cell's chromosomes, and is the place where almost all DNA replication and RNA synthesis (transcription) occur. The nucleus is spherical and separated from the cytoplasm by a double-membraned nuclear envelope. A space between the membranes is called the perinuclear space. The nuclear envelope isolates and protects a cell's DNA from various molecules that could accidentally damage its structure or interfere with its processing. During processing, DNA is transcribed, or copied into a special RNA, called messenger RNA (mRNA). This mRNA is then transported out of the nucleus, where it is translated into a specific protein molecule. The nucleolus is a specialized biomolecular condensate within the nucleus where ribosome subunits are assembled. It is one of several types of membrane-less nuclear bodies. Cells use DNA for their long-term information storage that is encoded in its DNA sequence. RNA is used for information transport (e.g., mRNA) and enzymatic functions (e.g., ribosomal RNA). Transfer RNA (tRNA) molecules are used to add amino acids during protein translation. The DNA of each cell is its genetic material, and is organized in multiple linear molecules, called chromosomes, that are coiled around histone proteins and housed in the cell nucleus. In humans, the nuclear genome is divided into 46 linear chromosomes, including 22 homologous chromosome pairs and a pair of sex chromosomes. The nucleus is a membrane-bound organelle.
=== Aquacobalamin reductase (NADPH) activity === Belongs to the oxidoreductase family, oxidizing metal ions with NADP+ acting as an electron acceptor. Uses FAD as a cofactor when catalyzing the following reaction: 2cob(II)alamin + NADP+ 2aquacob(III)alamin + NADPH + H+.
Sources: en.wikipedia.org
Major regulatory agencies have not approved it for any indication. Some countries permit it only under prescription frameworks, while others classify it as a controlled substance.
Much of the evidence comes from case reports and accounts of unregulated use rather than controlled trials. Differences in product purity and dosing add further variability.
Laboratory work focuses on receptor binding and cellular signalling. Observational reports document outcomes after use, and analytical chemists examine samples to assess content and purity.
No regulator in a major market has approved it for human use. It appears in research settings and in products marketed outside pharmacy channels. Legal status for personal possession varies by country.